Bill seeks to license pharma sales reps

Share this article:

The District of Columbia could become the first jurisdiction within the country to require the licensing of pharmaceutical sales representatives, pending the outcome of a bill being voted on in the local DC Council.

In December, the Council's representatives voted 7-6 in favor of the bill in its initial test.

That vote advanced the bill, dubbed the “SafeRx Act” to a vote at the council's next meeting in early January.

If passed, the Safe Rx Act bill sponsored by councilmember David Catania's (I-At Large) would require the formation of a pharmacy board to create a code of ethics for pharmaceutical salespeople and to license them.

Under the bill, DC reps would have to be college grads and would be prohibited from using titles that could lead doctors to think they are licensed to practice medicine, pharmacy, nursing or other fields of health.

The bill would also ban pharmaceutical manufacturers from using doctors' prescription data for marketing purposes without the doctors' knowledge.

Passage of the bill could pave the way for other states to pass similar legislation, say people on both sides of the debate.

Ken Johnson, PhRMA spokes-man, told The Washington Post that, “The DC government should not be trying to insert itself into an arena that is already well-covered nationwide by federal agencies. We should avoid the confusion of a patchwork quilt of local laws.”

About 3,000 to 4,000 sales representatives work in the DC region and cast a wide net outside the area, according to PhRMA.

Marjorie Powell, senior assistant general counsel for the association, told The Post that Catania's bill is “a misuse of the District's resources.”

However Catania contends that because their salaries are based on commission, pharma sales reps can mislead doctors and patients into buying the most expensive drugs on the market.

Councilman Marion Barry, a former mayor of Washington DC, is one of the DC councilmembers who opposes the bill. 

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...